Inhibikase Therapeutics Inc (IKT)

Cost of Revenue

$0.00

Quarterly · Period ending: · USD

IKT logo

IKT Cost of Revenue

Latest reported$0.00
IKT Quarterly Cost of Revenue ($256.89K → $0.00)
High-resolution chart · PNG

IKT cost of revenue history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Inhibikase Therapeutics Inc Cost of Revenue — Quarterly (USD)
Period endingCost of Revenue (USD)
0
0
0
0
0
0
6,567
6,568
6,569
6,568
6,568
6,568
159,204
5,043
5,042
1,681
2,982,183
3,016,991
3,390,258
3,154,553
2,382,433
2,431,860
226,944
120,569
263,175
283,114
267,915
254,967
474,047
1,555,781
1,345,077
585,291
797,399
256,890
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.